Leucodepletion for transmissible spongiform encephalopathies

British Journal of Biomedical Science

Volumn 61, Issue 1, 2004, Pages 48-54

  St Romaine, C ^a   Hazlehurst, G ^b   Jewell, A P ^a  

^a KINGSTON UNIVERSITY   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Creulzfeldt Jakob syndrome; Leucodepletion

Indexed keywords

B LYMPHOCYTE; BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; HEMATOLOGICAL PROCEDURES; HUMAN; INFECTION CONTROL; INFECTION RISK; LEUKODEPLETION; LYMPHOID TISSUE; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; REVIEW;

BOS TAURUS; BOVINAE;

EID: 1842483143     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2004.11732644     Document Type: Review

References (48)

1. Bird SM. Recipients of blood or blood products 'at vCJD risk'. BMJ 2004; 328: 118-9
2. Young K, Picarrdo P, Dloughy S, Bugiani O, Tagliavini F, Ghetti B. The human genetic prion diseases. In: Harris DA, ed. Prions. Molecular and cellular biology. Norfolk: Horizon Scientific Press, 1999.
3. Prusiner SB. Shattuck Lecture - Neurogenerative diseases and prions. N Engl J Med 2001; 344: 1516-26.
4. Brown P, Raubertas RF, Gajdusek DC, Castaigne P. The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature. Neurology 1987; 37: 895-904.
5. Esmonde TFG, Will RG, Slattery JM et al. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993; 341: 205-7.
6. Klein A, Frigg R, Flechsig E et al. A crucial role for B cells in neuroinvasine scrapie. Nature 1997; 390: 687-90.
7. Heye N, Hensen S, Muller,N. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1994; 343: 298-9.
8. Creange A, Gray F, Cesaro P, Degos JD. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet 1996; 347: 482.
9. Operskalski EA, Mosley JW. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet 1995; 346: 1224.
10. Evatt B, Austin H, Barhart E et al. Surveillance for Creutzfeldt-Jakob disease among persons with haemophilia. Transfusion 1998; 38: 817-20.
11. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
12. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5.
13. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-90.
14. Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that 'new variant' CJD is caused by BSE agent. Nature 1997; 389: 498-501.
15. Hill AF, Desbruslias M, Joiner S, Sidle KCL, Gowland I, Collinge J. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448-50.
16. Almond J, Patterson J. Human BSE. Nature 1997; 389: 437-8.
17. Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100.
18. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703-4.
19. Klein MA, Frigg R, Raeber AJ et al. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med 1998; 4: 1429-33.
20. Mabbot NA, Farquhar CF, Brown KL, Bruce ME. Involvement of the immune system in TSE pathogenesis. Immunol Today 1998; 19: 201-3.
21. Hill AF, Butterworth RJ, Joiner S et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183-9.
22. Klein R. Transmission of Creutzfeldt-Jakob disease by blood transfusion. Lancet 1993; 341: 768.
23. Foster PR, Welch AG, McLean C et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78: 86-95.
24. Will RG, Kimberlain RH. Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sang 1998; 75: 178-80.
25. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-6.
26. Ludham CA. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet 1997; 350: 1704.
27. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-50.
28. Foster PR. Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999; 9: 3-14.
29. Turner M. Variant Creutzfeldt-Jakob disease and the risk of transmission by blood transfusion. Transfus Today 1999; 40: 3-5.
30. MacGregor I, Hope J, Barnard G et al. Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sang 1999; 77: 88-96.
31. National Blood Service. Donor health questionnaire, 2002. Ref FRM/MED/CS/001/01.
32. UKNBS/NIBSC. Guidelines for the blood transfusion services in the United Kingdom. Norwich: HMSO, 2000.
33. Brown P, Preece MA, Will RG. 'Friendly fire' in medicine: hormones, homografts and Creutzfeldt-Jakob disease. Lancet 1992; 340: 24-7.
34. Robinson AE. vCJD and the possibility of transfusion transmission: the UK perspective. Transfus Today 2000; 45: 5-8.
35. Roos RP. Controlling new prion diseases. N Engl J Med 2001; 344: 1548-51.
36. Watkins AM. Creutzfeldt-Jakob disease and blood transfusion. BMJ 1991; 302: 1537.
37. Norfolk DR, Williamson LM. Leucodepletion of blood products by filtration. Blood Rev 1995; 9: 7-14.
38. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy coat poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841-5.
39. Goodnough LT, Ridell IVJ, Lazarus H et al. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993; 65: 103-7.
40. Bowden RA, Slichter SJ, Sayers M et al. A comparison of filtered leucocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transmission-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
41. McDonald CP, Cook R, Engel A, Robbins S, Rayfield I, Barbara JAJ. Robotic selective sampling and total automation for anti-CMV screening. Transfus Med 1999; 9: 301-5.
42. Pamphilon DH, Rider JR, Barbara JAJ, Williamson LM. Prevention of transfusion-transmitted cytomegalovirus infection. Transfus Med 1999; 9: 115-23.
43. Williamson LM, Rider JR, Swann ID, Winter MA, Ali F, Pamphilon DH. Evaluation of plasma and red cells obtained after leucocyte depletion of whole blood. Transfus Med 1999; 9: 51-61.
44. Murphy, M. New-variant Creutzfeldt-Jakob disease (nvCJD): the risk of transmission by blood transfusion and the potential benefit of leucocyte-reduction of blood components. Transfus Med Rev 1999; 13: 75-83.
45. Seghatchian J. Universal leucodepletion: an overview of some unresolved issues and the highlights of lessons learned. Transfus Apher Sci 2003; 29: 105-17.
46. Department of Health. http://www.info.doh.gov.uk /doh/intpress.nsf/page/ 2004-0004?OpenDocument.
47. Varney SJ, Guest JF. The annual cost of blood transfusion in the UK. Transfus Med 2003; 13: 205-18.
48. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease and its transmission by blood. J Thromb Haemost 2003; 1: 1479-86.